How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

161 results for

Pemoline

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Pemoline

Pemoline Pemoline Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pemoline Pemoline Aka: Pemoline , Cylert II. Indications (...) VII. Adverse Effects Hepatic failure of dysfunction Choreoathetoid movements Other adverse effects similar to VIII. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Pemoline." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Pemoline (C0030800) Definition (NCI) An oxazolidine compound with central nervous system (CNS) stimulant

2018 FP Notebook

2. Pemoline

Pemoline Pemoline Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pemoline Pemoline Aka: Pemoline , Cylert II. Indications (...) VII. Adverse Effects Hepatic failure of dysfunction Choreoathetoid movements Other adverse effects similar to VIII. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Pemoline." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Pemoline (C0030800) Definition (NCI) An oxazolidine compound with central nervous system (CNS) stimulant

2015 FP Notebook

3. Clinical trial of pemoline in general practice. (PubMed)

Clinical trial of pemoline in general practice. 4618123 1975 09 05 2013 11 21 0007-0947 28 11 1974 Nov The British journal of clinical practice Br J Clin Pract Clinical trial of pemoline in general practice. 375-8 Kagan G G eng Clinical Trial Journal Article Randomized Controlled Trial England Br J Clin Pract 0372546 0007-0947 0 Placebos 7GAQ2332NK Pemoline IM Adult Aged Anxiety Clinical Trials as Topic Depression drug therapy Family Practice Fatigue drug therapy Female Humans Male Middle Aged (...) Pemoline administration & dosage therapeutic use Placebos 1974 11 1 1974 11 1 0 1 1974 11 1 0 0 ppublish 4618123

1975 The British journal of clinical practice

4. Pemoline in the treatment of psychogenic fatigue in general practice. (PubMed)

Pemoline in the treatment of psychogenic fatigue in general practice. 366596 1979 03 28 2013 11 21 0032-6518 221 1323 1978 Sep The Practitioner Practitioner Pemoline in the treatment of psychogenic fatigue in general practice. 425-7 Valle-Jones J C JC eng Clinical Trial Journal Article Randomized Controlled Trial England Practitioner 0404245 0032-6518 7GAQ2332NK Pemoline IM Adult Clinical Trials as Topic Double-Blind Method Family Practice Fatigue drug therapy psychology Female Humans Pemoline

1979 The Practitioner

5. Pharmacokinetics of pemoline in plasma, saliva and urine following oral administration. (Full text)

Pharmacokinetics of pemoline in plasma, saliva and urine following oral administration. 1 Pemoline concentrations were measured in plasma and saliva following a single oral dose (37.5 or 50.0 mg) to healthy volunteers. In addition urinary excretion rates and cumulative urinary excretion of the parent compound and its oxazolidinedione metabolite were determined. 2 The plasma curves exhibited a mean elimination half-live of 11.0 +/- 1.2 h (n=4). Peak levels were reached at 2.7 +/- 0.6 h (n=4

1979 British journal of clinical pharmacology PubMed

6. Effects of magnesium pemoline and dextroamphetamine on human learning. (PubMed)

Effects of magnesium pemoline and dextroamphetamine on human learning. Two central nervous system stimulants, magnesium pemoline and dextroamphetamine, were tested to see if they facilitate learning in human subjects. Subjects under placebo learned faster than the subjects under any of the several doses of magnesium pemoline; however, none of these differences reached statistical significance. Subjects who received dextroamphetamine learned significantly more slowly than those who received

1967 Science (New York, N.Y.)

7. Effects of pemoline on hyperactive boys. (PubMed)

Effects of pemoline on hyperactive boys. Thirty boys rated as hyperactive by their teachers and parents received penoline or placebo in a double blind design. A variety of measures were taken during the nine week blind period. Behavior ratings were made on the Conners scale at 4 time intervals showing that a significant improvement in the drug group was observed by the teachers, but no significant change occurred in the ratings by the parents and physician. No toxic or grossly abnormal results

1976 Pharmacology, biochemistry, and behavior

8. Clinical trial with amantadine and pemoline in elderly patients. (PubMed)

Clinical trial with amantadine and pemoline in elderly patients. In a controlled clinical trial, amantadine 400 mg daily, 200 mg daily and 200 mg daily given with 20 mg of pemoline daily were compared with placebo in the treatment of elderly patients suffering from involutional cerebropathy characterized by psychomotor slowing down. The results showed that amantadine 400 mg daily was superior to placebo but was associated with a high incidence of side-effects (37 per cent), amantadine 200 mg

1976 Age and ageing

9. The clinical and psychological effects of pemoline in depressed patients--a controlled study. (PubMed)

The clinical and psychological effects of pemoline in depressed patients--a controlled study. The clinical and psychological effects of pemoline were compared with placebo in a double-blind study of 20 depressed patients. Target symptoms were disturbances of concentration and memory, tension, depression, fatigue, decreased libido, anorexia and insomnia. The two groups were matched for their clinical picture, age, sex, and duration of illness. During the three-week study period the pemoline (...) group received 50 mg daily. Significant differences in some clinical symptoms were found between the groups, but not in the performance of psychological tests, administered before and after the three-week study period. These differences proved the effectiveness of pemoline in combating symptoms of disturbances in concentration, memory, tension, depression and fatigue.

1979 International pharmacopsychiatry

10. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. (PubMed)

or relaxation, (RR 0.45, 95% CI 0.21 to 0.94, 1 study, n = 15), pemoline (RR 0.48, 95% CI 0.29 to 0.77, 1 RCT, n = 46), promethazine (RR 0.24, 95% CI 0.11 to 0.55, 1 RCT, n = 34), insulin (RR 0.52, 95% CI 0.29 to 0.96, 1 RCT, n = 20), branched chain amino acids (RR 0.79, 95% CI 0.63 to 1.00, 1 RCT, n = 52), and isocarboxazid (RR 0.24, 95% CI 0.08 to 0.71, 1 RCT, n = 20). There was low- to very low-certainty evidence of no difference between intervention and placebo or no treatment for the following

2018 Cochrane

11. Pharmacological treatment for memory disorder in multiple sclerosis (Full text)

include: acetylcholinesterase inhibitors (AChEI) (such as donepezil and rivastigmine), psychostimulants (methylphenidate, L‐amphetamine sulphate, modafinil, amantadine and pemoline), N‐methyl‐D‐aspartate (NMDA) antagonist (such as memantine) and some other pharmacological agents (such as Ginkgo biloba (GB) extracts, aminopyridines and cannabinoids). How the intervention might work The beneficial effects of DMDs may occur in the short term due to the anti‐inflammatory effects of the therapy

2018 European Academy of Neurology PubMed

12. Perinatal substance use: maternal

) • Sertraline (Zoloft, Zydep, Septrone) Amphetamines 5 • Amphetamine (AMPH) • Dextroamphetamine • Methamphetamine Amphetamine related • Benzphetamine • Diethylpropion • Ephedrine 5 • Fenfluramine • Mazindol • Methcathinone • Methylphenidate (Ritalin) • Pemoline • Phendimetrazine • Phentermine • Phenylpropanolamine CNS depressants Alcohol 5,9,10 Barbiturates 5 GHB (Gamma– hydroxybutrate) 5 Some solvents and inhalants 5 Benzodiazepines 5,10 • Alprazolam • Clonazepam • Diazepam • Flunitrazepam • Oxazepam

2016 Queensland Health

13. Pharmacological treatments for fatigue associated with palliative care. (Full text)

of the methods of blinding and allocation concealment, and the small size of the study populations. We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis. Treatment results pointed to weak and inconclusive evidence for the efficacy of amantadine, pemoline and modafinil in multiple sclerosis and for carnitine and donepezil in cancer-related fatigue (...) . Methylphenidate and pemoline seem to be effective in patients with HIV, but this is based only on one study per intervention, with only a moderate number of participants in each study. Meta-analysis shows an estimated superior effect for methylphenidate in cancer-related fatigue (standardised mean difference (SMD) 0.49, 95% confidence interval (CI) 0.15 to 0.83). Therapeutic effects could not be described for dexamphetamine, paroxetine or testosterone. There were a variety of results for the secondary

2015 Cochrane PubMed

15. Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. (PubMed)

in PubMed, Embase, Medline, Google Scholar, Cochrane Library (August 31, 2016). Search terms included multiple sclerosis, fatigue, medication treatments, amantadine, modafinil, aspirin, acetyl-l-carnitine, pemoline, 4-aminopyridine and randomized controlled trial (RCT). Two researchers were required to independently assess the quality of literatures, and finish data extraction. Meta-analysis was conducted using RevMan 5.3 software.A total of 11 RCTs involving 723 patients were included. The therapeutic (...) aspirin or 4-aminopyridine was beneficial. Finally, we found that all drugs except pemoline were relatively safe for treating MS fatigue.Current limited data suggest that amantadine may be the only drug that has relatively sufficient evidences in treatment of fatigue symptoms in MS. Further RCT studies recruiting larger samples sizes are required to validate the therapeutic effect of these candidate drugs.Copyright © 2017. Published by Elsevier B.V.

2017 Journal of the neurological sciences

16. Histaminergic Basis of Central Fatigue in Multiple Sclerosis

to cause fatigue such as severe anemia, infections, chronic systemic infectious or inflammatory disorders, including known autoimmune disorders. Chronic fatigue syndrome Hypothyroidism Systemic malignancy Undergoing chemotherapy Depression Sleep disorders including narcolepsy, excessive day-time sleep. History of substance abuse Excessive consumption of coffee or over-the-counter stimulants Concomitant medications of amantadine, methylphenidate, amphetamines, pemoline, barbiturates, tizanidine

2017 Clinical Trials

17. The Effectiveness of Short- and Long-Acting Stimulant Medications for Adolescents With ADHD in a Naturalistic Secondary School Setting. (PubMed)

of this approach.This study investigates stimulant medication effectiveness and adherence in a sample of adolescents with ADHD who were observed in their natural secondary school environment.Results indicated that the effect of stimulant medication on adolescent functioning is smaller in naturalistic settings than in previous analogue studies. Long-acting pemoline produced greater adherence than the short-acting methylphenidate (MPH), but parents and adolescents preferred the short-acting MPH.Overall, adolescents

2017 Journal of attention disorders

18. A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease

of informed consent Treatment with any of the following drugs within the past 2 weeks from the date of informed consent CNS stimulants: methylphenidate, modafinil, pemoline, atomoxetine Typical antipsychotics: bromperidol, chlorpromazine, haloperidol Anticholinergics: atropine, glycopyrrolate, scopolamine, homatropine, ipratropium (short term [within 3 days] use of anticholinergics for the purpose of antispasmodic action on the digestive system is permitted.) Abnormal blood test findings as follows

2017 Clinical Trials

19. Should stimulants be administered to manage difficulties with attention, hyperactivity and impulsivity following paediatric acquired brain injury?

OR amphetamine OR pemoline). Search Outcome Dissertations, non-English language papers and pharmaceutical company registers were excluded. Of 4192 papers retrieved, 16 were relevant to the question see the table. Relevant Paper(s) Author, date and country Patient group Study type (level of evidence) Outcomes Key results Study Weaknesses Mulhern et al, 2004 N=83 with ALL or BT (aged 6.7–17.9). Max dosage 20 mg twice daily. Treatment period 5 days RCT (level 2b) Behavioural questionnaires of hyperactivity

2012 BestBETS

20. A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

; norepinephrine reuptake inhibitors, such as tomoxetine (STRATTERA®) within 30 days prior to Day -1; antihypertensive agents, including diuretics, are not permitted at any time prior to or during the study; sedating antihistamines (as a single preparation or in combination) within 7 days prior to Day -1; sympathomimetics, appetite suppressants, modafinil, methylphenidate, amphetamine and pemoline within 7 days prior to Day -1; Use over the counter medications within 7 days of Investigational Product

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>